An expanded access record providing Everolimus in Metastatic Renal Cell Cancer, sponsored by Novartis Pharmaceuticals. No longer available at 85 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-08-19.
Sponsored by Novartis Pharmaceuticals · Expanded access
This expanded access study is designed to provide RAD001 to patients with MRCC who are without satisfactory treatment alternatives, until RAD001 becomes commercially available.
1,965 studies on the registry are indexed under Carcinoma, Renal Cell; 378 are open to participants now.
Browse Carcinoma, Renal Cell studies →Novartis Pharmaceuticals is the lead sponsor of 2,673 studies on the registry; 228 are open to participants now.
Of its 576 completed or terminated interventional studies of FDA-regulated products, 431 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Novartis Pharmaceuticals